Effect of hematopoietic stem cells transplantation on ICGR15 in patients with end-stage liver disease_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LUO Le , YAO Yutong , WEI Lingling , DENG Shaoping ,  HUANG Xiaolun

Department of Hepatobiliary Pancreatic and Splenic Surgery and Cell Transplantation Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital，Chengdu，Sichuan 610072, P.R.China;

Corresponding?author：

HUANG Xiaolun, Email: huangxiaolun@med.uestc.edu.cn

Keywords：

autologous peripheral blood CD34⁺ hematopoietic stem cell; end-stage liver disease; indocyanine green retention rate at 15 min; Child-Pugh classification of liver function

DOI：

10.7507/1007-9424.201612026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the changes of indocyanine green retention rate at 15 minutes (ICGR15) of autologous peripheral blood CD34⁺ hematopoietic stem cells transplantation in end-stage liver disease (end-stage liver, disease, ESLD) patients with different Child-Pugh grades during before and after transplantation of 3, 6, 12, 36, and 60 months. Methods The CD34⁺ hematopoietic stem cells transplantation were performed in 60 cases of advanced liver cirrhosis with different Child-Pugh grades who were ineffectively treated with strictly conservative treatment and complied with the criterion of liver transplantation. The ICGR15 were performed before transplantation and in 3, 6, 12, 36 and 60 months after transplantation. And the results of each time point in each Child-Pugh classification group were compared, and the rate of change of ICGR15 value were compared between each Child-Pugh classification group. Results The ICGR15 values of the Child-Pugh grading groups all decreased with time. In Child A group, there were respectively significant differences between the 6 months, 12 months, 36 months, and 60 months groups after transplantation and preoperative and 3 months groups after transplantation (P<0.05), but there was no significant difference between preoperative and 3 months group after transplantation (P>0.05), and there was significant difference between the 12 months and the 60 months group after transplantation (P<0.05). As same as Child A group, there were also significant differences between that time groups in the Child B group (P<0.05), but there were also significant differences between the 3 months group after transplantation and preoperative (P<0.05), and there were respectively significant differences between the 6 months and 12 months, 36 months, and 60 months group after transplantation in the Child B group (P<0.05). Also in the Child C group, there were significant differences between that time groups (P<0.05), but there was no significant difference between preoperative and 3 months group after transplantation (P>0.05), and there were respectively significant differences between the 6 months and 12 months, 36 months, and 60 months group after transplantation (P<0.05). There was no significant difference in the rate of ICGR15 between Child-Pugh classification groups. Conclusion Autologous peripheral blood CD34⁺ hematopoietic stem cells transplantation can effectively improve the liver function reserve capacity of ESLD patients and improve the safety of operation for a long time.

Citation： LUO Le, YAO Yutong, WEI Lingling, DENG Shaoping, HUANG Xiaolun. Effect of hematopoietic stem cells transplantation on ICGR15 in patients with end-stage liver disease. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(4): 443-448. doi: 10.7507/1007-9424.201612026 Copy

1.	?Margini C, Vukotic R, Brodosi L, et al. Bone marrow derived stem cells for the treatment of end-stage liver disease. World J Gastroenterol, 2014, 20(27): 9098-9105.
2.	Jang YO, Kim YJ, Baik SK, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int, 2014, 34(1): 33-41.
3.	Huang XL, Luo L, Luo LY, et al. Clinical outcome of autologous hematopoietic stem cell infusion via hepatic artery or portal vein in patients with end-stage liver diseases. Chin Med Sci J, 2014, 29(1): 15-22.
4.	姚豫桐, 羅蘭云, 薛華, 等. 自體外周血 CD34⁺ 干細胞移植治療晚期肝硬化 100 例的臨床療效分析. 中華肝病雜志, 2014, 22(9): 667-670.
5.	駱樂, 薛華, 羅蘭云, 等. 自體外周血 CD34⁺ 造血干細胞移植治療晚期肝硬化的遠期療效. 中華消化外科雜志, 2016, 15(7): 709-714.
6.	賈繼東, 李蘭娟. 慢性乙型肝炎防治指南(2010 年版). 中華內科雜志, 2011, 16(2): 1-12.
7.	衛生和計劃生育委員會衛生公益性行業科研專項專家組. 門靜脈高壓癥食管胃曲張靜脈破裂出血治療技術規范專家共識(2013 版). 中華消化外科雜志, 2014, 13(6): 401-404.
8.	董家鴻, 鄭樹森, 陳孝平, 等. 肝切除術前肝臟儲備功能評估的專家共識(2011 版). 中華消化外科雜志, 2011, 10(1): 20-25.
9.	Mizuguchi T, Kawamoto M, Meguro M, et al. Preoperative liver function assessments to estimate the prognosis and safety of liver resections. Surg Today, 2014, 44(1): 1-10.
10.	Nanashima A, Abo T, Tobinaga S, et al. Prediction of indocyanine green retention rate at 15 minutes by correlated liver function parameters before hepatectomy. J Surg Res, 2011, 169(2): e119-e125.
11.	Sheng QS, Lang R, He Q, et al. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis. Hepatobiliary Pancreat Dis Int, 2009, 8(1): 46-49.
12.	Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant Proc, 2006, 38(3): 801-802.
13.	羅皓, 王瑞豐, 陳濤, 等. 吲哚氰綠測定與 Child-Pugh 分級在肝儲備評估中的價值. 中國普外基礎與臨床雜志, 2011, 18(12): 1314-1316.
14.	陸森, 黃新立, 李相成, 等. 吲哚氰綠清除試驗在半肝切除術中應用的價值. 中國普外基礎與臨床雜志, 2010, 17(6): 543-546.
15.	Lorenzini S, Gitto S, Grandini E, et al. Stem cells for end stage liver disease: How far have we got? World J Gastroenterol, 2008, 14(29): 4593-4599.
16.	Pai M, Zacharoulis D, Milicevic MN, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34⁺cells into patients with alcoholic liver cisshosis. Am J Gastroenterol, 2008, 103(8): 1952-1958.
17.	Salama H, Zekri AR, Bahnassy AA, et al. Autologous CD34⁺and CD133⁺ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol, 2010, 16(42): 5297-5305.
18.	am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133⁺bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells, 2005, 23(4): 463-470.
19.	Ismail A, Fouad O, Abdelnasser A, et al. Stem cell therapy improves the outcome of liver resection in cirrhotics. J Gastrointest Cancer, 2010, 41(1): 17-23.
20.	Gong P, Wang Y, Wang Y, et al. Effect of bone marrow mesenchymal stem cells on hepatocellular carcinoma in microcirculation. Tumour Biol, 2013, 34(4): 2161-2168.
21.	Gong P, Wang Y, Zhang J. Bone marrow mesenchymal stem cells in hepatocellular carcinoma. Front Biosci (Landmark Ed), 2013, 18: 811-819.
22.	Su X, Zhang L, Ye J, et al. Bone marrow mesenchymal stem cells suppress ascitogenous hepatoma progression in BALB/c mouse through reducing myeloid-derived suppressor cells. Biomed Mater Eng, 2015, 25(1 Suppl): 167-177.
23.	Zhang L, Su XS, Ye JS, et al. Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system. Stem Cell Res Ther, 2015, 6: 45.
24.	湯地, 李勛, 姜春林, 等. 術前 ICGR15 聯合標準殘肝體積對巨大肝細胞癌精準肝切除術后肝功能不全的預測價值. 中華肝臟外科手術學電子雜志, 2015, 4(4): 222-226.

1. ?Margini C, Vukotic R, Brodosi L, et al. Bone marrow derived stem cells for the treatment of end-stage liver disease. World J Gastroenterol, 2014, 20(27): 9098-9105.
2. Jang YO, Kim YJ, Baik SK, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int, 2014, 34(1): 33-41.
3. Huang XL, Luo L, Luo LY, et al. Clinical outcome of autologous hematopoietic stem cell infusion via hepatic artery or portal vein in patients with end-stage liver diseases. Chin Med Sci J, 2014, 29(1): 15-22.
4. 姚豫桐, 羅蘭云, 薛華, 等. 自體外周血 CD34⁺ 干細胞移植治療晚期肝硬化 100 例的臨床療效分析. 中華肝病雜志, 2014, 22(9): 667-670.
5. 駱樂, 薛華, 羅蘭云, 等. 自體外周血 CD34⁺ 造血干細胞移植治療晚期肝硬化的遠期療效. 中華消化外科雜志, 2016, 15(7): 709-714.
6. 賈繼東, 李蘭娟. 慢性乙型肝炎防治指南(2010 年版). 中華內科雜志, 2011, 16(2): 1-12.
7. 衛生和計劃生育委員會衛生公益性行業科研專項專家組. 門靜脈高壓癥食管胃曲張靜脈破裂出血治療技術規范專家共識(2013 版). 中華消化外科雜志, 2014, 13(6): 401-404.
8. 董家鴻, 鄭樹森, 陳孝平, 等. 肝切除術前肝臟儲備功能評估的專家共識(2011 版). 中華消化外科雜志, 2011, 10(1): 20-25.
9. Mizuguchi T, Kawamoto M, Meguro M, et al. Preoperative liver function assessments to estimate the prognosis and safety of liver resections. Surg Today, 2014, 44(1): 1-10.
10. Nanashima A, Abo T, Tobinaga S, et al. Prediction of indocyanine green retention rate at 15 minutes by correlated liver function parameters before hepatectomy. J Surg Res, 2011, 169(2): e119-e125.
11. Sheng QS, Lang R, He Q, et al. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis. Hepatobiliary Pancreat Dis Int, 2009, 8(1): 46-49.
12. Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant Proc, 2006, 38(3): 801-802.
13. 羅皓, 王瑞豐, 陳濤, 等. 吲哚氰綠測定與 Child-Pugh 分級在肝儲備評估中的價值. 中國普外基礎與臨床雜志, 2011, 18(12): 1314-1316.
14. 陸森, 黃新立, 李相成, 等. 吲哚氰綠清除試驗在半肝切除術中應用的價值. 中國普外基礎與臨床雜志, 2010, 17(6): 543-546.
15. Lorenzini S, Gitto S, Grandini E, et al. Stem cells for end stage liver disease: How far have we got? World J Gastroenterol, 2008, 14(29): 4593-4599.
16. Pai M, Zacharoulis D, Milicevic MN, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34⁺cells into patients with alcoholic liver cisshosis. Am J Gastroenterol, 2008, 103(8): 1952-1958.
17. Salama H, Zekri AR, Bahnassy AA, et al. Autologous CD34⁺and CD133⁺ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol, 2010, 16(42): 5297-5305.
18. am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133⁺bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells, 2005, 23(4): 463-470.
19. Ismail A, Fouad O, Abdelnasser A, et al. Stem cell therapy improves the outcome of liver resection in cirrhotics. J Gastrointest Cancer, 2010, 41(1): 17-23.
20. Gong P, Wang Y, Wang Y, et al. Effect of bone marrow mesenchymal stem cells on hepatocellular carcinoma in microcirculation. Tumour Biol, 2013, 34(4): 2161-2168.
21. Gong P, Wang Y, Zhang J. Bone marrow mesenchymal stem cells in hepatocellular carcinoma. Front Biosci (Landmark Ed), 2013, 18: 811-819.
22. Su X, Zhang L, Ye J, et al. Bone marrow mesenchymal stem cells suppress ascitogenous hepatoma progression in BALB/c mouse through reducing myeloid-derived suppressor cells. Biomed Mater Eng, 2015, 25(1 Suppl): 167-177.
23. Zhang L, Su XS, Ye JS, et al. Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system. Stem Cell Res Ther, 2015, 6: 45.
24. 湯地, 李勛, 姜春林, 等. 術前 ICGR15 聯合標準殘肝體積對巨大肝細胞癌精準肝切除術后肝功能不全的預測價值. 中華肝臟外科手術學電子雜志, 2015, 4(4): 222-226.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Effect of hematopoietic stem cells transplantation on ICGR15 in patients with end-stage liver disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content